杰富瑞将清晰制药的目标价格下调33%至每股4.70澳元
杰富瑞继续维持对Clarity Pharmaceuticals Ltd. (CU6)的买入评级。
Clarity Pharmaceuticals的目标价被Bell Potter下调48%至每股5.20澳元
Canaccord Genuity重申对Clarity Pharmaceuticals Ltd. (CU6)的买入评级。
Jefferies将Clarity Pharmaceuticals的目标价格下调15%至每股7.00澳元
威尔逊重申对Clarity Pharmaceuticals Ltd. (CU6)的买入评级。
威尔逊坚持为Clarity Pharmaceuticals Ltd. (CU6) 维持买入评级。
Jefferies将Clarity Pharmaceuticals的目标股价上调11%至A$8.20/每股分享
贝尔波特获得买入评级:Clarity Pharmaceuticals Ltd.(CU6)
Clarity Pharmaceuticals的目标股价由Bell Potter从A $4.00上调至A $10.00/Share
Jefferies坚持对Clarity Pharmaceuticals Ltd. (CU6)的买入评级。